A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
- Published In:
- Human reproduction (Oxford, England), 32(9), 1915-1924 (2017)
- Authors:
- Abbara, Ali, Clarke, Sophie, Islam, Rumana, Prague, Julia K, Comninos, Alexander N, Narayanaswamy, Shakunthala, Papadopoulou, Deborah, Roberts, Rachel, Izzi-Engbeaya, Chioma, Ratnasabapathy, Risheka, Nesbitt, Alexander, Vimalesvaran, Sunitha, Salim, Rehan, Lavery, Stuart A, Bloom, Stephen R, Huson, Les, Trew, Geoffrey H, Dhillo, Waljit S
- Database ID:
- RPEP-03192
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03192APA
Abbara, Ali; Clarke, Sophie; Islam, Rumana; Prague, Julia K; Comninos, Alexander N; Narayanaswamy, Shakunthala; Papadopoulou, Deborah; Roberts, Rachel; Izzi-Engbeaya, Chioma; Ratnasabapathy, Risheka; Nesbitt, Alexander; Vimalesvaran, Sunitha; Salim, Rehan; Lavery, Stuart A; Bloom, Stephen R; Huson, Les; Trew, Geoffrey H; Dhillo, Waljit S. (2017). A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.. Human reproduction (Oxford, England), 32(9), 1915-1924. https://doi.org/10.1093/humrep/dex253
MLA
Abbara, Ali, et al. "A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.." Human reproduction (Oxford, 2017. https://doi.org/10.1093/humrep/dex253
RethinkPeptides
RethinkPeptides Research Database. "A second dose of kisspeptin-54 improves oocyte maturation in..." RPEP-03192. Retrieved from https://rethinkpeptides.com/research/abbara-2017-a-second-dose-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.